CAMP4 reports FY2024 net loss $51.8M; cash $64M, Phase 1 data expected Q4 2025

Camp4 Therapeutics Corp

Net loss of $51.8M for FY2024 vs $49.3M in FY2023; R&D expenses $38.8M, G&A $14.9M.
Cash and equivalents $64.0M as of Dec 31, 2024; sufficient to fund into Q2 2026.
Phase 1 trial of CMP-CPS-001 for UCDs ongoing; SAD completed safely, MAD dosing in progress; safety, PK, PD data expected Q4 2025.
Phase 1b trial in female OTC heterozygotes expected Q2 2025 in Australia, Europe to follow.
Development candidate CMP-SYNGAP-01 nominated for SYNGAP1-related disorders; GLP tox studies planned 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.